Please check your internet connection and try again.
# Metronidazole
## Overview
Metronidazole is an antibiotic and antiprotozoal agent effective against anaerobic bacteria and certain protozoa.
## Primary Indications
* **Bacterial Vaginosis:** Primary treatment.
* **Trichomoniasis:** Primary treatment.
* **Giardiasis:** Primary treatment.
* **Amebiasis:** Intestinal and extraintestinal infections.
* **Anaerobic Bacterial Infections:** Intra-abdominal infections, gynecologic infections, skin and soft tissue infections, bone and joint infections, CNS infections, bacterial vaginosis, C. difficile infection (in select cases).
* **Helicobacter pylori Eradication:** Part of combination therapy.
* **Surgical Prophylaxis:** Particularly in colorectal surgery.
## Adult Dosing
* **Bacterial Vaginosis:**
* Oral: 500 mg twice daily for 7 days OR 2 g as a single dose.
* Vaginal Gel 0.75%: One applicatorful (5 g) intravaginally once daily for 5 days.
* **Trichomoniasis:**
* Oral: 2 g as a single dose OR 250 mg three times daily for 7 days OR 375 mg twice daily for 7 days.
* **Giardiasis:**
* Oral: 250 mg three times daily for 5 days.
* **Amebiasis:**
* Oral: 500-750 mg three times daily for 5-10 days.
* **Anaerobic Bacterial Infections:**
* Oral/IV: 500 mg every 8 hours. Usual duration 7-10 days.
* **C. difficile Infection:**
* Oral: 500 mg every 8 hours for 10-14 days (alternative to vancomycin for initial episode, mild-to-moderate disease).
* **H. pylori Eradication:**
* Oral: 500 mg twice daily for 10-14 days as part of a triple or quadruple therapy regimen.
* **Surgical Prophylaxis:**
* Oral/IV: 500 mg to 1 g before surgery, repeated every 8-12 hours for up to 24 hours post-operatively.
## Pediatric Dosing
Dosing is weight-based and depends on the indication. Consult specific pediatric guidelines.
* **Bacterial Infections:** 15-30 mg/kg/day divided into 3 doses (maximum 400 mg per dose or 2 g/day).
* **Amebiasis:** 35-50 mg/kg/day divided into 3 doses (maximum 750 mg/dose) for 5-10 days.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment typically needed. However, if using IV formulations with high sodium content, monitor fluid status.
* **Hepatic Impairment:** Use with caution. May require dose reduction in severe hepatic dysfunction.
## Contraindications
* Hypersensitivity to metronidazole or other nitroimidazoles.
* First trimester of pregnancy (though often used if benefits outweigh risks and alternatives are unsuitable).
* Concomitant use of disulfiram or alcohol (within 3 days of last dose).
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal pain, metallic taste, headache, dark urine.
* **Serious:** Peripheral neuropathy (especially with prolonged use), seizures, encephalopathy, Stevens-Johnson syndrome, aseptic meningitis, pancreatitis, dizziness, ataxia.
## Key Drug Interactions
* **Alcohol:** Disulfiram-like reaction (flushing, nausea, vomiting, headache, tachycardia). Avoid alcohol during and for at least 3 days after therapy.
* **Disulfiram:** Concomitant use can lead to psychosis, confusion. Avoid.
* **Warfarin:** Potentiates anticoagulant effect. Monitor INR closely and adjust warfarin dose as needed.
* **Lithium:** May increase lithium levels. Monitor lithium levels.
* **Phenytoin/Phenobarbital:** May decrease metronidazole levels.
* **Fluorouracil (5-FU):** May increase fluorouracil toxicity.
## Monitoring
* Signs and symptoms of infection resolution.
* Adverse effects, particularly peripheral neuropathy (numbness, tingling) and CNS effects.
* INR if patient is on warfarin.
* Lithium levels if concomitantly used.
## Clinical Pearls
* Advise patients to avoid alcohol during treatment and for at least 3 days after finishing.
* The metallic taste is common and usually resolves after discontinuation.
* Neuropathy can be irreversible; report any signs or symptoms immediately.
* For vaginal gel, avoid sexual intercourse during treatment.
* Ensure adequate hydration when administering IV metronidazole.
---
*Disclaimer: This information is intended for clinical professionals. Always consult the most current prescribing information and local protocols for definitive guidance.*